FDA links intravenous glutathione reactions to supplement-grade ingredient

FDA expands its warning

The Food and Drug Administration issued a compounding risk alert on August 27 after receiving reports involving at least 30 patients who experienced adverse events following intravenous glutathione, either alone or combined with other ingredients. Some patients were hospitalized, and the agency said it continues to receive reports while its investigation remains active.

The common link identified by FDA was a lot of glutathione supplied by Medisca Inc. The material, lot 229536, was labeled as dietary-supplement grade. FDA said that designation makes it inappropriate for producing injectable drugs because ingredients manufactured for oral supplement use may not meet the specifications or contamination controls required for intravenous administration.

Glutathione is an endogenous tripeptide involved in cellular antioxidant defenses. The alert, however, is not a finding about glutathione’s normal biology or evidence that every formulation poses the same risk. It concerns compounded injectable products made with a particular category and lot of ingredient.

Reports followed two pharmacy recalls

FDA said two Texas pharmacies conducted recalls after elevated endotoxin levels were detected in compounded glutathione injections. Victory Medical Center Pharmacy announced its recall on August 5, covering three lots of 200-milligram-per-milliliter multidose vials distributed in Texas, Florida and New York. The pharmacy reported reactions including fever, chills, severe headache, nausea, vomiting, rapid heartbeat, blood-pressure changes, body aches and injection-site reactions.

Optimal Balance Pharmacy announced a separate recall on August 19, which FDA published the following day. That recall covered one lot of the same concentration distributed across 13 states. The company reported fever, chills, severe headache, nausea, vomiting, pain and symptoms consistent with an allergic reaction.

The August 27 alert connected the broader group of reported events to pharmacies that obtained glutathione from the same Medisca lot. FDA said Medisca notified its U.S. customers on August 20 not to use its dietary-supplement-grade glutathione in compounded injectable drugs.

Reported symptoms across the investigation included fever, chills, pain, dizziness, signs of shock and sepsis-like illness. FDA characterized those reports as consistent with excessive endotoxin exposure but did not state that every reported event had been conclusively caused by endotoxin or the identified ingredient lot.

Why the route of administration matters

Bacterial endotoxins can trigger powerful inflammatory responses when introduced into the bloodstream. FDA notes that excessive exposure may cause muscle pain, headache, nausea, vomiting, low blood pressure, shock and death, although not all of those outcomes were reported in this investigation.

An ingredient suitable for swallowing is therefore not automatically suitable for injection. Intravenous administration bypasses barriers in the digestive tract and places a preparation directly into circulation. FDA’s alert emphasizes that quality must be established through appropriate sourcing and manufacturing controls, rather than relying only on finished-product testing.

The episode also repeats a documented problem. In 2019, FDA investigated reactions associated with compounded injectable glutathione made from material labeled as a dietary ingredient. Laboratory analysis at that time confirmed excessive endotoxin in sampled powder, and the agency warned that material intended for supplements should not be used in sterile injectable drugs.

What remains unknown

The current alert is based on safety surveillance, recall testing and an ongoing regulatory investigation, not a controlled clinical study. Public records do not provide a denominator showing how many people received products made from the implicated lot, so an adverse-event rate cannot be calculated. Reports involving glutathione combined with other ingredients also complicate attribution.

The evidence nevertheless establishes a concrete manufacturing concern: multiple pharmacies used supplement-grade material from a shared lot, two recalls followed elevated-endotoxin findings, and patients reported illnesses compatible with endotoxin exposure. FDA’s immediate message is directed principally at compounders, ingredient suppliers and health professionals responsible for verifying that ingredients are appropriate for injectable use. Further investigation is needed to define the full distribution of the lot, the number and severity of cases, and the precise relationship between individual exposures and reported illnesses.